19186-33-5

Basic information

• Product Name: ARISTEROMYCIN
• Synonyms: (1r,2s,3r,5r)-3-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)-1,2-cyclopentanedi;1,2-cyclopentanediol,3-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)-,(1r,2s,3r,5;ARISTEROMYCIN;9-[2,3-DIHYDROXY-4-(HYDROXYMETHYL)CYCLOPENTYL]ADENINE;(1R,2S,3R,5R)-3-(6-Amino-9H-purin-9-yl)-5-(hydroxymethyl)-1,2-cyclopentanediol;4'-O-Carbaadenosine;Cycloadenosine;3-Aristeromycin
• CAS NO: 19186-33-5
• Molecular Formula: C₁₁H₁₅N₅O₃
• Molecular Weight: 265.27
• Mol File: 19186-33-5.mol
• Article Data: 17

Chemical Properties

• Melting Point: 213～215℃
• Boiling Point: 595.1°Cat760mmHg
• Flash Point: 313.7°C
• Appearance: /
• Density: 1.92g/cm³
• Vapor Pressure: 5.19E-15mmHg at 25°C
• Refractive Index: 1.881
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ARISTEROMYCIN(CAS DataBase Reference)
• NIST Chemistry Reference: ARISTEROMYCIN(19186-33-5)
• EPA Substance Registry System: ARISTEROMYCIN(19186-33-5)

Safety Data

• WGK Germany: 3
• RTECS: GY4250000
• Hazardous Substances Data: 19186-33-5(Hazardous Substances Data)

Usage

Uses

Aristeromycin is an antibacterial adenosine analog.

InChI:InChI=1/C11H15N5O3/c12-10-7-11(14-3-13-10)16(4-15-7)6-1-5(2-17)8(18)9(6)19/h3-6,8-9,17-19H,1-2H2,(H2,12,13,14)/t5-,6-,8-,9+/m1/s1

Upstream product

• 5413-85-4 5-amino-4,6-dichloropyridimine 
• 78-39-7 Triethyl orthoacetate 
• 132342-52-0 ((3aR,4R,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)methanol 
• 123826-82-4 9-<(1'R,2'S,3'R,4'R)-4-(tert-butoxymethyl)-2,3-(cyclohexylidenedioxy)cyclopentan-1-yl>adenine 
• 131603-36-6 Benzoic acid (1R,2R,3S,4R)-4-(6-benzoylamino-purin-9-yl)-3-benzyloxy-2-hydroxy-cyclopentylmethyl ester 
• 147332-45-4 (1α,4α)-4-(6-Amino-9H-purin-9-yl)-2-cyclopentenylcarbinol 
• 151266-98-7 9-<(1R,2S,3R)-4-t-butyldimethylsiloxymethyl-2,3-isopropylidenedioxycyclopentan-1-yl>adenine 
• 58462-31-0 (1R,2S,3R,5R)-3-(6-chloro-9H-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol 
• 188118-68-5 Acetic acid (1R,2R,3S,4R)-4-(6-benzoylamino-purin-9-yl)-2,3-dihydroxy-cyclopentylmethyl ester 
• 106665-46-7 N-(9-((1R,2S,3R,4R)-2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl)-9H-purin-6-yl)benzamide 
• 174171-97-2 (1'R,2'R,3'S,4'R)-4'-(6-aminopurin-9-yl)-1'-hydroxymethyl-2',3'-O-isopropylidenecyclopentane-2',3'-diol 
• 869710-95-2 (1S,4S)-4-Hydroxymethyl-cyclopent-2-enol 
• 869710-97-4 (1S,4S)-4-(tert-Butyl-diphenyl-silanyloxymethyl)-cyclopent-2-enol 
• 874910-84-6 Acetic acid (3aS,4R,6R,6aR)-6-(tert-butyl-diphenyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl ester 

Downstream Products

• 97336-47-5 (1R,2S,3R,5R)-3-(6-Amino-purin-9-yl)-5-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-cyclopentane-1,2-diol 
• 118149-16-9 C₃₉H₃₁N₅O₇ 
• 16975-94-3 <1R,2S,3R,4R-(1α,2β,3β,4α)>-D-1,9-dihydro-9-<2,3-dihydroxy-4-(hydroxymethyl)cyclopentyl>-6H-purin-6-one 
• 264610-92-6 N⁶-methyl-2'-O-[phenoxy(thiocarbonyl)]-3',5'-O-(tetraisopropyldisiloxa-1,3-diyl)adenosine 
• 264610-95-9 carbocyclic N⁶-methyl-2'-deoxyadenosine-3',5'-bis(dibenzyl phosphate) 
• 106665-50-3 N-(9-((1R,3S,4R)-3-hydroxy-4-(hydroxymethyl)cyclopentyl)-9H-purin-6-yl)benzamide 
• 110558-74-2 N-(9-((1R,3R,4S)-3-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-4-hydroxycyclopentyl)-9H-purin-6-yl)benzamide 
• 118188-68-4 C₃₂H₂₆FN₅O₅ 
• 118149-17-0 C₃₂H₂₇N₅O₆ 
• 118149-20-5 C₃₃H₂₆F₃N₅O₈S 
• 97336-49-7 (1S,2R,3R,5R)-5-(6-Amino-purin-9-yl)-3-[bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-2-(tert-butyl-dimethyl-silanyloxy)-cyclopentanol 
• 97336-50-0 9-[(1R,2S,3R,4R)-4-[Bis-(4-methoxy-phenyl)-phenyl-methoxymethyl]-2,3-bis-(tert-butyl-dimethyl-silanyloxy)-cyclopentyl]-9H-purin-6-ylamine 
• 138284-89-6 (1R,4S)-2-Amino-1,9-dihydro-9-<4-(hydroxymethyl)cyclopent-2-enyl>purin-6-one Triphosphate 

Relevant articles and documents

A 9-step enantiospecific synthesis of (-)-aristeromycin from D-ribonic acid γ-lactone

-

3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR

The present disclosure relates to 3'3'-cyclic dinucleotides comprising a carbocyclic nucleotide and derivatives thereof, that can modulate the activity of the STING adaptor protein.

Chiral syntheses of 6′-β-fluoroaristeromycin, 6′-β-fluoro-5′-noraristeromycin and aristeromycin

Carbocyclic nucleosides substituted at the C-6′ position are receiving increasing attention. Chiral synthetic accessibility to the biologically promising 6′-β-fluoroaristeromycin is lacking. Its preparation and that of the 5′-nor analogue are described. A